Poseida Therapeutics, Inc. (PSTX) Misses Q4 EPS by 56c

Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q4 EPS of ($0.39), $0.56 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $10.05 million versus the consensus estimate of $61.69 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Meta reaches $18 billion deal with 52 attorneys general on teen safety
• Williams-Sonoma (WSM) Tops Q2 EPS by 4c